Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prognostic Value Of A Lactate Metabolism Gene Signature In Lung Adenocarcinoma And Its Associations With Immune Checkpoint Blockade Therapy Response.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Prognostic Value Of A Lactate Metabolism Gene Signature In Lung Adenocarcinoma And Its Associations With Immune Checkpoint Blockade Therapy Response.

Related Experiment Video

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

Prognostic value of a lactate metabolism gene signature in lung adenocarcinoma and its associations with immune checkpoint blockade therapy response.

Tengfei Huang1, DuoHuang Lian1, MengMeng Chen1

  • 1Department of Thoracic and Cardiac Surgery, The 900th Hospital of the Joint Logistics Support Force of the People's Liberation Army, Fuzhou, Fujian Province, China.

Medicine
|October 28, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study identifies an eight-gene signature related to lactate metabolism that predicts survival in lung adenocarcinoma (LUAD). This signature also correlates with immune cell infiltration and response to immune checkpoint blockade therapy.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.9K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Lung adenocarcinoma (LUAD) is a major cause of cancer-related mortality.
  • Lactate metabolism plays a crucial role in tumor progression and immune evasion.
  • Identifying prognostic biomarkers for LUAD is essential for improving patient outcomes.

Purpose of the Study:

  • To investigate the prognostic value of lactate metabolism genes in LUAD.
  • To develop a gene signature for predicting LUAD patient survival and treatment response.
  • To explore the relationship between lactate metabolism, tumor immunity, and immune checkpoint blockade (ICB) therapy.

Main Methods:

  • Analysis of LUAD expression and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases.
  • Utilized LASSO Cox and stepwise Cox regression to identify an eight-lactate metabolism gene signature.
  • Evaluated differences in immune infiltration, tumor mutation burden (TMB), and response to ICB therapy between risk groups.

    • Main Results:

    • An eight-lactate metabolism gene signature was developed, demonstrating independent prognostic value in LUAD.
    • High-risk groups exhibited significantly poorer survival outcomes.
    • Significant differences in immune cell infiltration, tumor purity, TMB, and predicted ICB response (TIDE, CYT scores) were observed between risk groups.

    Conclusions:

    • The 8-lactate metabolism gene signature effectively predicts patient survival and immune characteristics in LUAD.
    • This signature may serve as a biomarker for predicting response to immune checkpoint blockade therapy.
    • Targeting lactate metabolism pathways could offer novel therapeutic strategies for LUAD patients.